2024

PromarkerD results for predicting kidney decline in type 1 diabetes published in peer-reviewed journal

Esophageal cancer diagnostic delivers excellent results

Investor Presentation – Pitt Street Research Life Sciences Conference

Appointment of Director – Dr James Williams

Update on commercialisation of PromarkerD in the USA

Annual Report to shareholders

New results – PromarkerD & type 1 diabetes

Corporate Governance Statement and Appendix 4G

Resignation of Director and Appendix 3Z

Quarterly Activities Report June 2024 – Appendix 4C

Notification of cessation of securities

Application for quotation of securities – PIQ

Eurobio Scientific to sell PromarkerD DKD test in France

Notification regarding unquoted securities

Issue of Equity Incentives to Employees

Appointment of medical device sales agency in EU

Promarker technology diagnosing plant dieback

Quarterly Activities Report March 2024 – Appendix 4C

Investor Presentation

Proteomics International signs agreement with University of Oxford to further validate PromarkerEndo test for endometriosis

PromarkerD US commercialisation & Promarker pipeline update

Proteomics International retains its ISO13485 certification

European patent granted for OxiDx technology

Financial report for the half-year ended 31 December 2023

Investor presentation – Euroz Hartleys Healthcare Forum

Study validates biomarkers for endometriosis blood test

Study validates biomarkers for oesophageal cancer blood test

Becoming a substantial holder

Investor Presentation

Change in substantial holding – Lipscombe

Change of Director’s Interest Notice – Lipscombe

Application for quotation of securities

Proposed issue of securities – PIQ – Ordinary Fully Paid

Prospectus

Proteomics to raise $6.5m through Institutional Placement

Proposed issue of Securities – PIQ – Ordinary Fully Paid

Quarterly Activities Report December 2023 – Appendix 4C